G.G. Torgomyan1,2, N.M. Kiselev1,2, V.E. Zagainov1,2, S.V. Gamayunov2
1Privolzhsky Research Medical University, Nizhny Novgorod
2Nizhny Novgorod Regional Clinical Oncological Dispensary, Nizhny Novgorod
Torgomyan Gaik G. ― Assistant of the Department of Faculty Surgery and Transplantation of the Privolzhsky Research Medical University; oncologist of the Nizhny Novgorod Regional Clinical Oncological Dispensary
11/1 Delovaya Str., Nizhny Novgorod, 603093, Russian Federation, tel. +7-987-536-46-72, e-mail: t995aik@mail.ru, ORCID ID: 0000-0002-8927-239X
Abstract. Squamous cell carcinoma of the esophagus today remains one of the leading cancer morbidity and mortality rates. This paper analyzes the main treatment options that are currently widely used in the treatment of resectable squamous cell carcinoma of the esophagus and possible directions for development in the treatment of such patients. Much attention has been paid to immunotherapy, both alone and in combination with chemotherapy or radiation therapy in patients in the neoadjuvant setting.
Key words: esophageal cancer, immunotherapy, chemotherapy, squamous cell carcinoma, neoadjuvant chemotherapy, neoadjuvant chemoimmunotherapy, esophageal cancer immunotherapy.